

Call for Grant Applications CFG-PD-2025 AbbVie Independent Education (IE)

Therapeutic Area/Disease State	Parkinson's disease
Focus	Mitigation and Management of Infusion Site Events
	with Subcutaneous Infusions in Parkinson's Disease
Issue Date:	Wednesday, April 30
Due Date/CFG Close Date:	Wednesday, June 11

Decision Date and Notification

Once AbbVie has reached a decision about the grant application, a system-generated email notification will be sent. If the request is approved, the Authorized Signer identified in the grant application must log into the AbbVie grant management system to review and approve the Letter of Agreement. The Letter of Agreement must be electronically signed by all parties prior to the activity start date. Please do not consider any request approved until an email notification is received from AbbVie stating that the grant request is approved.

Background

With the emergence of subcutaneous infusion therapies for the management of advanced Parkinson's disease, there remains limited understanding by Movement Disorder Specialists and General Neurologists about the identification, mitigation and management strategies for infusion site events that occur with therapy.

Eligibility Criteria:

Grant applicants must be U.S.-based and registered in AbbVie's Grant Management System at grants.abbvie.com with no outstanding reconciliations.

Transparency

AbbVie and the AbbVie grant review and approval process complies with applicable laws, regulations, recommendations and guidance, including, without limitation: guidance from the Department of Health & Human Services Office of Inspector General (OIG), Pharmaceutical Research and Manufacturers of America (PhRMA), Advanced Medical Technology Association (AdvaMed), the Accreditation Council for Continuing Medical Education (ACCME), the Physician Payments Sunshine Act (commonly known as the "Sunshine Act" or "Open Payments"), and internal AbbVie policies and procedures.



AbbVie, at its sole discretion, may disclose the details of funded independent medical education activities, including as may be required by federal, state, and/or local laws and regulations. This disclosure may include, but shall not be limited to, details of the activity and the grant amount.

Terms and Conditions

AbbVie reserves the right to approve or deny any or all grant applications received as a result of this Call for Grants (CFG) or to cancel, in part or in its entirety, this CFG. AbbVie is not responsible for any costs associated with this CFG submission.

Submission Directions

- 1. Please go to grants.abbvie.com and sign in. First-time users should click "Register"
- 2. In the grant application:
 - STEP 1. Select "Submit New Request" to start the submission process.
 - STEP 2. Select the "Education Requests" button to continue the submission process.
 - STEP 3. Read the Request Submission Instructions and click "Proceed" to enter the request form.
 - STEP 4. Enter Request Information on the General Information Tab.
 - o In the Activity Sub-Type field, select Independent Medical Education
 - Under Therapeutic Area, select <u>Neuroscience Parkinsons</u>
 - In the Program Title field, start the title of the grant request as: CFG-PD-2025
 - STEP 5. Continue entering requested information as outlined in the grant application, including document uploads.
- 3. If you have questions or require assistance, please contact:

AbbVie Independent Education Department at abbviegrants@abbvie.com.

IMPORTANT: Grant applications submitted in response to this Call for Grants after the due date will not be reviewed by the AbbVie Independent Education Department and will be automatically declined. In addition, grant applications must include the required information outlined in the Submission Directions. Failure to provide this information may result in the grant application being declined.

Call for Grant Details

Therapeutic Area/Disease state	Neuroscience/Parkinson's Disease
Target Audience	Movement Disorder Specialists and General
	Neurologists (including Advanced Practice Providers)
Geographic Scope	United States



Submission Deadline	Wednesday, June 11
Anticipated Notification	July
Budget	\$250,000.00

Statement of Need:

In the U.S., subcutaneous infusions for the management of motor fluctuations in advanced Parkinson's disease have recently emerged on the market. This modality for treatment is new to Movement Disorder Specialists and General Neurologists. As the use of these therapies increases in the management of motor fluctuations, it will be important to build confidence and education around the prevention/mitigation, identification, and management of infusion site events most commonly observed with these therapies, supporting their safe and effective use.